The importance of myeloid-derived suppressor cells in the regulation of autoimmune effector cells by a chronic contact eczema

Journal of Immunology

Volumn 179, Issue 8, 2007, Pages 5071-5081

  Marhaba, Rachid ^a   Vitacolonna, Mario ^a   Hildebrand, Dagmar ^a   Baniyash, Michal ^c   Freyschmidt Paul, Pia ^d   Zöller, Margot ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF KARLSRUHE   (Germany)

^c HEBREW UNIVERSITY   (Israel)

^d UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD31 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR8; CYTOKINE; GAMMA INTERFERON RECEPTOR; GR 1 PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; PROTEIN; PROTEIN BCL 2; PROTEIN KINASE ZAP 70; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; ALLERGEN; ANTIGEN T CELL RECEPTOR, ZETA CHAIN; CYCLOBUTANE DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN; SQUARIC ACID DIBUTYL ESTER;

ALOPECIA AREATA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOIMMUNITY; BONE MARROW CELL; CELL ACTIVATION; CELL POPULATION; CELL PROLIFERATION; CHRONIC DISEASE; COMPARATIVE STUDY; CONTACT DERMATITIS; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; HAIR GROWTH; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LYMPH NODE CELL; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; SENSITIZATION; SKIN SENSITIZATION; SPLEEN CELL; SUPPRESSOR CELL; T LYMPHOCYTE; ANIMAL; AUTOIMMUNE DISEASE; BIOSYNTHESIS; C3H MOUSE; CYTOLOGY; DELAYED HYPERSENSITIVITY; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ALLERGENS; ALOPECIA AREATA; ANIMALS; AUTOIMMUNE DISEASES; CHRONIC DISEASE; CYCLOBUTANES; DERMATITIS, CONTACT; DOWN-REGULATION; HYPERSENSITIVITY, DELAYED; MEMBRANE PROTEINS; MICE; MICE, INBRED C3H; MYELOID CELLS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, REGULATORY;

EID: 38449108094     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.8.5071     Document Type: Article

References (62)

1. Valitutti, S., S. Muller, M. Salio, and A. Lanzavecchia. 1997. Degradation of T cell receptor (TCR)-CD3-ζ complexes after antigenic stimulation. J. Exp. Med. 185: 1859-1864.
2. D'Oro, U., M. S. Vacchio, A. M. Weissman, and J. D. Ashwell. 1997. Activation of the Lck tyrosine kinase targets cell surface T cell antigen receptors for lysosomal degradation. Immunity 7: 619-628.
3. Bronstein-Sitton, N., L. Wang, L. Cohen, and M. Baniyash. 1999. Expression of the T cell antigen receptor ζ-chain following activation is controlled at distinct checkpoints: implications for cell surface receptor down-modulation and re-expression. J. Biol. Chem. 274: 23659-23665.
4. Viola, A., and A. Lanzavecchia. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273: 104-106.
5. Chikuma, S., and J. A. Bluestone. 2003. CTLA-4 and tolerance: the biochemical point of view. Immunol. Res. 28: 241-253.
6. Jang, I. K., and H. Gu. 2003. Negative regulation of TCR signaling and T-cell activation by selective protein degradation. Curr. Opin. Immunol. 15: 315-320.
7. Germain, R. N., and I. Stefanova. 1999. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu. Rev. Immunol. 17: 467-522.
8. Samelson, L. E. 2002. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu. Rev. Immunol. 20: 371-394.
9. + regulatory T cells. Immunol. Rev. 212: 60-73.
10. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212: 8-27.
11. + regulatory T cells. Semin. Immunol. 16: 89-98.
12. Serafini, P., I. Borrello, and V. Bronte. 2006. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer. Biol. 16: 53-65.
13. Baniyash, M. 2006. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin. Cancer. Biol. 16: 80-88.
14. Kusmartsev, S., and D. I. Gabrilovich. 2006. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev. 25: 323-331.
15. + myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 176: 2085-2094.
16. Ezernitchi, A. V., I. Vaknin, L. Cohen-Daniel, O. Levy, E. Manaster, A. Halabi, E. Pikarsky, L. Shapira, and M. Baniyash. 2006. TCR ζ down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J. Immunol. 177: 4763-4772.
17. Gabrilovich, D. I., V. Bronte, S. H. Chen, M. P. Colombo, A. Ochoa, S. Ostrand-Rosenberg, and H. Schreiber. 2007. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67: 425.
18. Bronstein-Sitton, N., L. Cohen-Daniel, I. Vaknin, A. V. Ezernitchi, B. Leshem, A. Halabi, Y. Houri-Hadad, E. Greenbaum, Z. Zakay-Rones, L. Shapira, and M. Baniyash. 2003. Sustained exposure to bacterial antigen induces interferon-γ-dependent T cell receptor ζ down-regulation and impaired T cell function. Nat. Immunol. 10: 957-964.
19. + T cells. J. Clin. Invest. 116: 2777-2790.
20. Frey, A. B. 2006. Myeloid suppressor cells regulate the adaptive immune response to cancer. J. Clin. Invest. 116: 2587-2590.
21. Rodriguez, P. C., D. G. Quiceno, and A. C. Ochoa. 2007. L-arginine availability regulates T lymphocyte cell cycle progression. Blood 109: 1568-1573.
22. Serafini, P., K. Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte, and I. Borrello. 2006. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203: 2691-2702.
23. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11: 6713-6721.
24. Terabe, M., S. Matsui, J. M. Park, M. Mamura, N. Noben-Trauth, D. D. Donaldson, W. Chen, S. M. Wahl, S. Ledbetter, B. Pratt, et al. 2003. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198: 1741-1752.
25. + cells producing nitric oxide. Cancer Res. 66: 11441-11446.
26. Baniyash, M. 2004. TCR ζ-chain downregulation: curtailing an excessive inflammatory immune response. Nat. Rev. Immunol. 4: 675-687.
27. Gilhar, A., and R. S. Kalish. 2006. Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun. Rev. 5: 64-69.
28. McElwee, K. J., K. Silva, D. Boggess, L. Bechtold, L. E. King, Jr., and J. P. Sundberg. 2003. Alopecia areata in C3H/HeJ mice involves leukocyte-mediated root sheath disruption in advance of overt hair loss. Vet. Pathol. 40: 643-650.
29. Paus, R., N. Ito, M. Takigawa, and T. Ito. 2003. The hair follicle and immune privilege. J. Investig. Dermatol. Symp. Proc. 8: 188-194.
30. Ross, E. K., and J. Shapiro. 2005. Management of hair loss. Dermatol. Clin. 23: 227-243.
31. Tobin, D. J., S. H. Gardner, N. J. Lindsey, R. Hoffmann, R. Happle, and P. Freyschmidt-Paul. 2002. Diphencyprone immunotherapy alters anti-hair follicle antibody status in patients with alopecia areata. Eur. J. Dermatol. 12: 327-334.
32. Holzer, A. M., L. L. Kaplan, and W. R. Levis. 2006. Haptens as drugs: contact allergens are powerful topical immunomodulators. J. Drugs Dermatol. 5: 410-416.
33. Sundberg, J. P., D. Boggess, X. Montagutelli, M. E. Hogan, and L. E. King, Jr. 1995. C3H/HeJ mouse model for alopecia areata. J. Invest. Dermatol. 104: 16-17.
34. Gardner, S., P. Freyschmidt-Paul, R. Hoffmann, J. P. Sundberg, R. Happle, N. J. Lindsey, and D. J. Tobin. 2000. Normalisation of hair follicle morphology in C3H/HeJ alopecia areata mice after treatment with squaric acid dibutylester. Eur. J. Dermatol. 10: 443-450.
35. Zöller, M., P. Freyschmidt-Paul, M. Vitacolonna, K. J. McElwee, S. Hummel, and R. Hoffmann. 2004. Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata. Clin. Exp. Immunol. 135: 398-408.
36. McElwee, K. J., D. Boggess, L. E. King, Jr., and J. P. Sundberg. 1998. Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using fullthickness skin grafts. J. Invest. Dermatol. 111: 797-803.
37. + cells blockade disease onset in the C3H/HeJ mouse model. J. Invest. Dermatol. 124: 947-957.
38. Marhaba, R., P. Freyschmidt-Paul, and M. Zöller. 2006. In vivo CD44-CD49d complex formation in autoimmune disease has consequences on T cell activation and apoptosis resistance. Eur. J. Immunol. 36: 3017-3032.
39. Mazzoni, A., V. Bronte, A. Visintin, J. H. Spitzer, E. Apolloni, P. Serafini, P. Zanovello, and D. M. Segal. 2002. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168: 689-695.
40. Rossner, S., C. Voigtlander, C. Wiethe, J. Hanig, C. Seifarth, and M. B. Lutz. 2005. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur. J. Immunol. 35: 3533-3544.
41. Franchin, G., and B. Diamond. 2006. Pulse steroids: how much is enough? Autoimmun. Rev. 5: 111-113.
42. + regulatory T-cell therapy for allergy, autoimmune disease and transplant rejection. Inflamm. Allergy Drug Targets 5: 239-242.
43. Tang, Q., and J. A. Bluestone. 2006. Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev. 212: 217-237.
44. Bunt, S. K., P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2006. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176: 284-290.
45. Zöller, M., K. J. McElwee, M. Vitacolonna, and R. Hoffmann. 2004. The progressive state, in contrast to the stable or regressive state of alopecia areata, is reflected in peripheral blood mononuclear cells. Exp. Dermatol. 13: 435-444.
46. Sinha, P., V. K. Clements, S. Miller, and S. Ostrand-Rosenberg. 2005. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol. Immunother. 54: 1137-1142.
47. + T cells. Blood 96: 3838-3846.
48. Wang, Y., and N. Sheibani. 2002. Expression pattern of alternatively spliced PECAM-1 isoforms in hematopoietic cells and platelets. J. Cell. Biochem. 87: 424-438.
49. Terabe, M., S. Matsui, J. M. Park, M. Mamura, N. Noben-Trauth, D. D. Donaldson, W. Chen, S. M. Wahl, S. Ledbetter, B. Pratt, et al. 2003. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198: 1741-1752.
50. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumorbearing host. Cancer Res. 66: 1123-1131.
51. Wang, G., T. Savinko, H. Wolff, M. C. Dieu-Nosjean, L. Kemeny, B. Homey, A. I. Lauerma, and H. Alenius. 2007. Repeated epicutaneous exposures to ovalbumin progressively induce atopic dermatitis-like skin lesions in mice. Clin. Exp. Allergy 37: 151-161.
52. Gupta, P., P. Freyschmidt-Paul, M. Vitacolonna, S. Kiessling, S. Hummel, D. Hildebrand, R. Marhaba, and M. Zöller. 2006. A chronic contact eczema impedes migration of antigen-presenting cells in alopecia areata. J. Invest. Dermatol. 126: 1559-1573.
53. Serafini, P., C. De Santo, I. Marigo, S. Cingarlini, L. Dolcetti, G. Gallina, P. Zanovello, and V. Bronte. 2004. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53: 64 -72.
54. Lizee, G., L. G. Radvanyi, W. W. Overwijk, and P. Hwu. 2006. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin. Cancer Res. 12: 4794 - 4803.
55. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172: 989-999.
56. Apolloni, E., V. Bronte, A. Mazzoni, P. Serafini, A. Cabrelle, D. M. Segal, H. A. Young, and P. Zanovello. 2000. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J. Immunol. 165: 6723-6730.
57. Tracey, L., A. Pérez-Rosado, M. J. Artiga, F. I. Comacho, A. Rodriguez, N. Martinez, E. Ruiz-Ballesteros, M. Mollejo, B. Martinez, M. Cuadros, et al. 2005. Expression of the NF-κB targets BCL2 and BIRC5/survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J. Pathol. 206: 123-134.
58. Chen, G., and D. V. Goeddel. 2002. TNF-R1 signaling: a beautiful pathway. Science 296: 1634-1635.
59. + myeloid cells. Cancer Res. 66: 6807-6815.
60. Schmielau, J., and O. J. Finn. 2001. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 61: 4756-4760.
61. Freyschmidt-Paul, P., K. J. McElwee, R. Hoffmann, J. P. Sundberg, M. Vitacolonna, S. Kissling, and M. Zöller. 2006. Interferon-γ-deficient mice are resistant to the development of alopecia areata. Br. J. Dermatol. 155: 515-521.
62. Ehrlich, L. I., P. J. Ebert, M. F. Krummel, A. Weiss, and M. M. Davis. 2002. Dynamics of p56lck translocation to the T cell immunological synapse following agonist and antagonist stimulation. Immunity 17: 809-822.